Phase III study evaluating palbociclib (PD-0332991), a CyclinDependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy.

    Study Chair
    Dr. Marco Colleoni, EIO Milano, Italy

    Statistician
    Valentina Nekljudova, GBG Forschungs GmbH, Neu-Isenburg, Germany

    Lead Trial Coordinators
    Holly Shaw

    Trial Monitors
    Giuseppe Achille, Daniela Celotto, Carmen Comune

    IBCSG Coordinating Center, Bern, Switzerland
    Phone: +41 31 511 94 00
    Fax: +41 31 511 94 01
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


    Date of Activation

    Targeted Accrual

    800


    International Breast
    Cancer Study Group

    Effingerstrasse 40
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: ibcsgcc@ibcsg.org

    Member Login